Genistein, a natural isoflavonoid found in soybean products, has been proposed to be associated with a lower rate of breast cancer in Asian women. Studies from our laboratory and others have shown that genistein can induce apoptosis by regulating the expression of apoptosis-related genes in breast cancer cells. However, the precise molecular mechanism(s) by which genistein induces apoptotic cell death is not clear. In order to investigate such mechanism, we tested the role of Akt and NF-jB in genistein-treated MDA-MB-231 breast cancer cells. We found that inhibition of cell growth and induction of apoptosis by genistein are partly mediated through the downregulation of Akt and NF-jB pathways. Gel shift assay showed that NF-jB DNA-binding activity in MDA-MB-231 cells transfected with Akt cDNA was induced, suggesting that there is a cross-talk between NFjB and Akt signaling pathway. Moreover, we found that genistein could abrogate EGF and Akt induced NF-jB activation. From these results, we conclude that the inactivation of NF-jB by genistein in MDA-MB-231 breast cancer cells is partly mediated via Akt pathway, which could be useful for rational design of strategies for the prevention and/or treatment of breast cancer.
Introduction
Epidemiological studies have shown wide geographical variations in the occurrence of breast cancer in women (Miller, 1977; Gray et al., 1979) . Asian women who consume traditional soy products have much lower incidence and mortality of breast cancer. However, as Asian women migrate to the United States, the incidence of breast cancer in their first and second generations increases (Buell, 1973; Hirayama, 1978) . Soy-based diets are high in isoflavonoid. Genistein, a natural isoflavonoid found in soybean products, has been proposed to be associated with a lower rate of breast cancer in Asian women (Fotsis et al., 1995; Lamartiniere et al., 1995) and is believed to be a chemopreventive agent (Lamartiniere et al., 1995) . Genistein has been known to compete with estradiol for estrogen receptor binding as weak estrogen (Bradlow and Sepkovic, 2002) , to regulate signal transduction as inhibitor of protein tyrosine kinases (Akiyama et al., 1987) , and to inhibit cellular oxidative stress (Wei et al., 1993) and angiogenesis (Fotsis et al., 1995 (Fotsis et al., , 1997 . The in vitro and in vivo experimental studies from our laboratory and other investigators have shown that genistein can inhibit the growth of various cancer cell lines through cell cycle arrest (G2/M) and downregulation of cyclin B1 and cdc25C, induce apoptosis through upregulation of p21 WAFI and Bax expression and activation of CPP32, and inhibit invasion of different tumor cells in vitro with downregulation of MMP-9 and upregulation of TIMP-1 (Constantinou et al., 1990; Spinozzi et al., 1994; Davis et al., 1998; Lian et al., 1998; Shao et al., 1998; Alhasan et al., 1999; Li et al., 1999a,b; Santibanez et al., 2000) . However, the mechanism(s) by which genistein elicits its pleiotropic effects on breast cancer cells has not been fully evaluated.
NF-kB is a key regulator of genes involved in cell activation and proliferation (Grilli et al., 1993) . NF-kB activity is normally regulated through its cytoplasmic sequestration by specific inhibitors including IkB and related proteins. Upon stimulation by a variety of stimuli including cytokines, radiation, and oxidative stress etc., IkB is phosphorylated by IkB kinase (IKK), allowing the release of NF-kB dimers to enter the nucleus and subsequent activation of target genes (Chen et al., 1996) . A recent report also suggests that NF-kB may be regulated by reversible acetylation (Chen et al., 2001) . NF-kB functions as an important mediator in apoptotic signaling pathways; it also plays critical roles in cell proliferation, cell adhesion, inflammation, differentiation, angiogenesis, and tumor cell invasion (Bharti and Aggarwal, 2002) . It has been reported that activated NF-kB blocks cellular apoptosis in several different cell types (Van Antwerp et al., 1996; Wang et al., 1999) , and that the inactivation of NF-kB makes cells more sensitive to apoptosis-inducing agents (Wang et al., 1998 ). An antiapoptotic role of NF-kB has also been suggested from an in vivo study where an embryonic lethality and liver degeneration was observed in mice lacking the RelA component of NF-kB (Beg et al., 1995) .
Since NF-kB plays important roles in many cellular processes, research on the interaction of NF-kB activation with other cell signal transduction pathways, including the PI3K/Akt pathway, has received increased attention in recent years. Akt is a serine/threonine kinase regulated by growth factors, and may be activated by a wide variety of growth stimuli, including EGF, PDGF, IGF, and NGF (Downward, 1998) . Akt activation occurs due to phosphorylation of Akt protein at Thr308 or Ser473 by PI3K (Alessi et al., 1996) and functions as an antiapoptotic signaling molecule. It has been reported that estrogenic compounds including genistein show a differential effect on Akt activation, depending on the ER status of cells (Brownson et al., 2002) . It has also been shown that Akt regulates NF-kB activation directly through activation of IKK or phosphorylation of RelA (Romashkova and Makarov, 1999; Sizemore et al., 1999) . A recent study from our laboratory also showed the inhibition of NF-kB DNAbinding activity in PC3 prostate cancer cells by genistein, which was partly mediated via the Akt signaling pathway (Li and Sarkar, 2002) . However, the status of Akt and NF-kB and their cross-talks during genistein-induced apoptosis in breast cancer cells has not been investigated. Here we report that pharmacological doses of genistein inhibit cell growth, induce apoptosis, and inhibit NF-kB activation through the Akt pathway in MDA-MB-231 breast cancer cells.
Results

Cell growth inhibition by genistein
The treatment of MDA-MB-231 breast cancer cells for 1-3 days with 5, 15, 30, and 50 mm of genistein resulted in inhibition of cell proliferation (Figure 1 ). The inhibition of cell growth was dose-and time-dependent, as observed previously (Li et al., 1999b) . Next, we explored whether the inhibition of cell proliferation was also accompanied by the induction of apoptosis induced by genistein as we have reported earlier (Li et al., 1999b) . Two different methods including DNA ladder and DNA/histone fragmentation analysis were employed to investigate the degree of apoptosis induced by genistein.
Genistein induces apoptosis in MDA-MB-231 cells
Apoptosis was observed in the MDA-MB-231 cells treated with 50 mm genistein (Figure 2 ). The induction of apoptosis was time-dependent and was found to be more pronounced at 48-72 h of treatment, confirming our earlier results (Li et al., 1999b) . Our results were highly reproducible in two independent experiments, which provided convincing data showing that genistein induces apoptosis in MDA-MB-231 cells. In order to further understand the molecular mechanism of genistein-induced apoptosis in MDA-MB-231 cells, alterations of cell survival pathway were investigated.
Inhibition of NF-kB activity by genistein
To investigate whether genistein modulated NF-kB DNA-binding activity in MDA-MB-231 breast cancer Inhibition of Akt and BF-j by genistein L Gong et al cells, electrophoretic mobility shift assay (EMSA) was performed ( Figure 3 ). Autoradiography revealed that NF-kB DNA-binding activity was decreased in cells treated with genistein for 48 h and it was more pronounced after 72 h of treatment. The specificity of NF-kB DNA binding was shown by supershift and the competition experiment in which the signal was abolished completely by competition with excess unlabeled NF-kB oligo. In contrast, a nonspecific oligonucleotide failed to compete the specific binding. The above results indicate that the induction of apoptosis by genistein may be potentially mediated by the downregulation of NFkB transcription factor activity which, in turn, may be responsible for both cell growth inhibition and induction of apoptotic processes.
We further investigated whether genistein could abrogate NF-kB induction by EGF. The treatment of MDA-MB-231 cells by EGF exhibited enhanced NF-kB DNA-binding activity as expected. However, when cells were pretreated with 50 mm genistein for 72 h prior to stimulation with EGF, we found that genistein was able to abrogate EGF-induced activation of NF-kB ( Figure 3 ). These results demonstrate that genistein not only inhibits NF-kB DNA-binding activity in unstimulated conditions, but also inhibits EGF-induced NF-kB activity.
Inhibition of Akt kinase activity by genistein
Since Akt kinase plays an important role in inhibiting apoptosis, we investigated the effect of genistein on Akt in MDA-MB-231 cells by Western blot, immunoprecipitation, and Akt kinase assays. We found that the expression of total Akt1 and phosphorylated Akt1 at Ser473 was downregulated in genistein-treated cells (Figure 4 ). The inhibition of p-AktSer473 was more pronounced with 50 mm genistein treatment at 48 h, and occurred earlier than total Akt1 inhibition. These results were further confirmed by Akt immunoprecipitation and kinase assays ( Figure 5 ), which showed decreased phosphorylation of GSK-3a/b caused by downregulation of p-AktSer473 in genistein-treated MDA-MB-231 cells. About 40% inhibition of GSK fusion protein phosphorylation was observed in cells treated with genistein compared to untreated control cells. Furthermore, when we compared the phosphorylation of GSK3a/b in genistein-treated and untreated cells followed by EGF stimulation, we found that pretreatment with genistein abrogated the Akt kinase activity induced by EGF ( Figure 5 ). Pretreatment with LY294002 also 
NF-kB inactivation is mediated via Akt pathway
We further investigated whether the effect of genistein is mechanistically mediated via Akt and NF-kB pathways. The cells transfected with pLNCX-Akt showed about four to five times higher luciferase activity, compared with control transfection, whereas there was no significant alteration in luciferase activity in cells transfected with dominant-negative Akt vector ( Figure 6 ). When the transfected cells were treated with 50 mm genistein for 36 h, the luciferase activity was inhibited by about 60% in cells transfected with pLNCX-Akt, and the EGF-induced luciferase activity was also abrogated in transfected cells by genistein ( Figure 6 ).
To confirm these results, we conducted EMSA to examine the NF-kB DNA-binding activity in cells transfected with pLNCX-Akt, pLNCX-Akt-K179M, or pLNCX. Compared to cells transfected with pLNCX vector (data not shown), functional pLNCX-Akt was able to induce NF-kB activity, whereas dominantnegative vector pLNCX-Akt-K179M has no effect on NF-kB activation. Genistein, like LY294002 (a PI3K inhibitor), inhibited NF-kB DNA-binding activity in pLNCX-Akt-transfected MDA-MB-231 cells with or without EGF stimulation (Figure 7) . These results provide evidence for a potential crosstalk between Akt and NF-kB pathways during genisteininduced cell growth inhibition and apoptosis in breast cancer cells.
Discussion
We and others have previously shown that genistein induces apoptosis in a variety of cancer cells including breast cancer MDA-MB-231 cells (Spinozzi et al., 1994; Davis et al., 1998; Lian et al., 1998; Alhasan et al., 1999; Li et al., 1999a,b) . In the present study, we not only confirmed our previous observation, but also showed that genistein has a dramatic effect on growth inhibition and induction of apoptotic processes in MDA-MB-231 cells as demonstrated by MTT assay and DNA fragmentation analysis. In addition, our current data provided mechanistic information that genistein exerts its proapoptotic effects on MDA-MB-231 cells by inhibiting phosphorylation of Akt and activation of NF-kB DNA-binding activity.
The cell survival oncoprotein Akt (also known as protein kinase B, PKB) is abnormally activated in many human malignancies. It can suppress apoptosis and promote cell proliferation through growth factormediated survival pathway (Blume-Jensen and Hunter, 2001). EGF-induced Akt activation also leads to phosphorylation and cytoplasmic localization of forkhead family transcription factors, showing an antiapoptotic effect (Brunet et al., 1999; Kane et al., 1999) . Zhou et al. also described that Her2/neu-induced Akt activation could be augmented by MDM-2-mediated degradation of p53 (Zhou et al., 2001b) and by inhibition of p21 WAFI translocation to the nucleus (Zhou et al., 2001a) . Recent reports have shown that activation of Akt contributes to resistance to antiproliferative signals during breast cancer progression, which may occur by impairing the nuclear import of p27, thus inhibiting p27-mediated G1 arrest (Liang et al., 2002; Viglietto et al., 2002) . These results strongly demonstrate the critical role of Akt in antiapoptotic processes, suggesting that Akt is an excellent target for cancer prevention and treatment. In our study, the expression of total Akt1 and phosphorylated Akt at Ser473 was downregulated by genistein in MDA-MB-231 cells. These results were Furthermore, we found that pretreatment of cells with genistein abrogated EGF-induced Akt kinase activity, which, in turn, inhibited the phosphorylation of GSK3a/b. It is important to note that active Akt phosphorylates its downstream targets including GSK-3a/b and cyclin D1. GSK-3 plays important roles in glycogen/ protein metabolism and cell cycle regulation. It has been reported that GSK-3a/b possesses apoptotic effects in mammalian cells (Bijur et al., 2000) . Once GSK-3a/b is phosphorylated by Akt, its proapoptotic activity is inhibited. GSK-a/b also modulates cell apoptosis through b-catenin. GSK-3a/b is constitutively active in unstimulated cells where it phosphorylates b-catenin, resulting in rapid degradation of b-catenin (Orford et al., 1997) . Inhibition of GSK-3a/b by active Akt allows bcatenin to accumulate in the cytoplasm and then translocate to the nucleus, where it interacts with transcription factors of the T-cell factor/lymphocyte enhancer-binding factor-1 (TCF/LEF-1), resulting in transcription of several genes including cyclin D1 (Dale, 1998; Arias et al., 1999; Blume-Jensen and Hunter, 2001) . A recent report has shown that P13K/Akt stimulates androgen pathway through GSK-3b inhibition and nuclear b-catenin accumulation, implicating the important roles of GSK-3 and b-catenin in hormone-related cancer (Sharma et al., 2002) . In addition to the inhibition of cyclin D1 through bcatenin, GSK-3b can also regulate cyclin D1 proteolysis and subcellular localization, resulting in cell cycle arrest (Diehl et al., 1998) . Based on our results, we speculate that one possible mechanism by which genistein induces apoptosis is due to inactivation of Akt, which leads to accumulation of GSK-3, inhibits proliferation, and induces apoptosis through abrogation of b-cateninmediated gene transcription. However, the antiapoptotic function of Akt could also be mediated by multiple pathways, including apoptotic cascade and cell cycle regulation. Therefore, genistein may also induce apoptosis by regulating other molecules, such as Bax and p21 WAFI , as reported previously (Lian et al., 1998; Li et al., 1999b) .
In the present study, we also found that genistein inhibited NF-kB DNA-binding activity and abrogated EGF-induced NF-kB activation in MDA-MB-231 cells. This could be another mechanism by which genistein inhibits cell growth and induces apoptosis. Akt has been shown to activate NF-kB by phosphorylation of IKK at a critical regulatory site Thr23 and subsequent degradation of IkB (Ozes et al., 1999; Romashkova and Makarov, 1999) . Additionally, Akt may also contribute to NF-kB regulation through p65/RelA phosphorylation, as observed in HepG3 cells during IL-1 stimulation, where it appears to be independent of IKK activation and ikB degradation (Sizemore et al., 1999) . Moreover, Akt has been found to enhance the degradation of IkB, which led to activation of NF-kB in the Jurkat T-cell line (Kane et al., 1999) . However, a recent report showed that Akt is a downstream target of NFkB, because overexpression of p65 led to higher Akt phosphorylation (Meng et al., 2002) . Our results obtained from gene transfection and NF-kB activity assays demonstrated that there is a crosstalk between Akt and NF-kB pathways. Activation of NF-kB appears to be mediated by Akt, and the inhibition of NF-kB activity by genistein treatment may be partly mediated by the Akt pathway. We also showed that EGF-induced activation of Akt and NF-kB could be abrogated by genistein through a similar mechanism. However, further in-depth experiments are needed to establish the precise molecular mechanism about the cause and effect relations between Akt and NF-kB during genistein-induced apoptosis in breast cancer cells.
In conclusion, we presented experimental evidence, which strongly support the antiproliferative and proapoptotic effects of genistein in MDA-MB-231 breast cancer cells. This effect is partly mediated by inactivation of Akt and NF-kB signaling pathways, which could be useful for devising novel preventive and therapeutic strategies against breast cancer.
Materials and methods
Cell culture and reagents
Human breast cancer cell line MDA-MB-231 was grown in DMEM/F12 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS and 1% penicillin and streptomycin in a 5% CO 2 atmosphere at 371C. Genistein (Toronto Research Chemicals, North York, ON, Canada) was dissolved in 0.1 m Na 2 CO 3 to make a 10 mm stock solution and was added directly to the media at different concentration. The PI3K inhibitor, LY294002 (Sigma, St Louis, MO, USA) was dissolved in DMSO and added to the culture media to make a final concentration of 25 mm and 0.01% DMSO. EGF (Invitrogen, Carlsbad, CA, USA) was added to the media at a final concentration of 100 ng/ml.
Cell growth inhibition studies by MTT assay
MDA-MB-231 cells (2 Â 10
3 ) were seeded in a 96-well culture plate and subsequently treated with 5, 15, 30, and 50 mm genistein for 24, 48, and 72 h, while control cells received 0.5 mm Na 2 CO 3 in culture medium. After treatment, the cells were incubated with MTT reagent (0.5 mg/ml; Sigma) at 371C for 2 h and then with isopropanol at room temperature for 1 h. Spectrophotometric absorbance of the samples was determined by an Ultra Multifunctional Microplate Reader (Tecan, Durham, NC, USA).
DNA ladder analysis for detection of apoptosis
For DNA ladder formation analysis, MDA-MB-231 cells treated with 50 mm genistein or 0.5 mm Na 2 CO 3 (control) for 24, 48, and 72 h were suspended in 0.3 ml lysis buffer (10 mm Tris (pH 8.0), 1 mm EDTA, and 0.2% Triton X-100) and centrifuged at 13 000 g for 10 min at 41C. The supernatant was then treated with RNase for 1 h, followed by SDS-Proteinase K digestion. Cellular cytoplasmic DNA was extracted with phenol chloroform, and precipitated with an equal volume of isopropanol. DNA was separated through a 1.5% agarose gel. After electrophoresis, gels were stained with ethidium bromide and the DNA was visualized by UV light.
Histone/DNA ELISA for detection of apoptosis
The Cell Death Detection ELISA Kit (Roche, Palo Alto, CA, USA) was used for assessing apoptosis in MDA-MB-231 cells treated with genistein according to the manufacturer's protocol. Briefly, MDA-MB-231 cells were treated with 50 mm Genistein or 0.5 mm Na 2 CO 3 (control) for 24, 48, and 72 h, respectively. After treatment, the cells were lysed and cell lysates were overlaid and incubated in microtiter plate modules coated with antihistone antibody. Then, samples were incubated with anti-DNA-peroxidase followed by color development with ABTS s substrate. The optical densities of the samples were determined by the Ultra Multifunctional Microplate Reader (Tecan, Durham, NC, USA) at 405 nm.
Western blot analysis
MDA-MB-231 cells were seeded in 100 mm dishes and allowed to attach for 24 h, followed by the addition of 30 and 50 mm Genistein or 0.5 mm Na 2 CO 3 (control), and incubated for 24, 48, and 72 h, respectively. After incubation, cells were lysed in a buffer containing 62.5 mm Tris-HCl and 2% SDS, sonicated for 3 Â 10 s. Protein concentration was measured using a BCA Protein Assay Kit (Pierce, Rockfbrd, IL, USA). Samples were resolved through a 10% SDS -polyacrylamide gel and then transferred to a nitrocellulose membrane. After blocking with 7.5% nonfat dry milk, each blot was incubated with monoclonal anti-Akt1 (epitope: amino acids 345-480 of Akt1, 1 : 500; Oncogene, San Diego, CA, USA), polyclonal anti-Akt2 (epitope: amino acids 455-469 of Akt2, 1 : 500; Santa Cruz Biotechnology, Santa Cruz, CA, USA), antiphospho-Akt Ser473 (1 : 1000; Cell Signaling, Beverly, MA, USA), or anti-b-actin (1 : 5000; Sigma) antibodies. The bound antibody was detected by secondary antibodies conjugated with peroxidase and analysed with the Supersignal Chemiluminescent Substrate (Pierce). The experiment was repeated twice.
Akt kinase assay
Akt kinase assay was performed using an Akt Kinase Assay Kit (Cell Signaling). Briefly, MDA-MB-231 cells were treated with genistein, EGF, genistein followed by EGF, LY294002 followed by EGF, or Na 2 Co 3 and lysed in cell lysis buffer containing 20 mm Tris-HCl (pH 7.5), 150 mm NaCl, 1 mm EDTA, 1 mm EGTA, 1% Triton X-100, 2.5 mm sodium pyrophosphate, 1 mm b-glycerolphosphate, 1 mm Na 3 VO 4 , 1 mg/ml leupeptin, and 1 mm PMSF on ice for 10 min. The protein concentration was measured using a BCA Protein Assay Kit (Pierce). Equal amounts of proteins (250 mg) were immunoprecipitated with 20 ml agarose-coupled anti-Akt antibody overnight at 41C. The immunocomplexes were collected by centrifugation, washed with cell lysis and kinase buffers, then subjected to Akt kinase assay in a 40 ml kinase buffer (25 mm Tris (pH 7.5), 5 mm b-glycerolphosphate, 2 mm DTT, 0.1 mm Na 3 VO 4 , and 10 mm MgCl 2 ) supplemented with 200 mm ATP and 1 mg GSK-3a/b fusion protein at 301C for 30 min. Phosphorylation of GSK-3a/b was measured by Western blot analysis using phospho-GSK-3a/b antibody. The experiment was repeated twice.
Reporter gene constructs and transfection pLNCX-Akt (wildtype Akt), pLNCX-Akt-K179M (dominant negative), and pLNCX (empty vector) were generously provided by Dr Sellers. The Akt expression plasmid pLNCX-Akt was created by PCR amplification of Akt cDNA and cloning into pLNCX vector. pLNCX-Akt-K179M was created by site-directed mutagenesis and served as dominantnegative Akt (Ramaswamy et al., 1999) . NF-kB-Luc (Stratagene, La Jolla, CA, USA) contains six repeated copies of the NF-kB DNA-binding site and a luciferase reporter. CMV-bgal reporter plasmid transfection was used for normalization of transfection efficiency. The pLNCX-Akt, pLNCX-Akt-K179M, or pLNCX was transiently cotransfected with NFkB-Luc and CMV-b-gal into MDA-MB-231 cells by LipofectAMINE (Invitrogen). After incubation for 5 h, the transfected cells were washed and complete medium was added. After culture overnight, the cells were then treated with genistein for 36 h, genistein for 36 h followed by EGF for 30 min, EGF alone for 30 min, or LY294002 for 1 h followed by EGF for 30 min. The cells were lysed and lysates were assayed for luciferase activity by a Steady-Glo Luciferase assay system (Promega, Madison, WI, USA) using an Ultra Multifunctional Microplate Reader (Tecan). The experiment was repeated twice.
For detecting NF-kB activity by EMSA, MDA-MB-231 cells were transiently transfected with pLNCX-Akt, pLNCXAkt-K179M, or pLNCX together with CMV-b-gal by LipofectAMINE (Invitrogen). After incubation for 5 h, the transfected cells were washed and cultured overnight in complete medium. Cells were then treated with genistein for 36 h, genistein for 36 h followed by EGF for 30 min, EGF alone for 30 min, or LY294002 for 1 h followed by EGF for 30 min. The cells were lysed and nuclear proteins were extracted, as described earlier (Li and Sarkar 2002) . Nuclear proteins (10 mg) were subjected to EMSA.
EMSA for measuring NF-kB activity
MDA-MB-231 cells were seeded in 100 mm dishes and allowed to attach for 24 h. Then, the cells were treated with 30 and 50 mm genistein or Na 2 CO 3 (control) for 24, 48, 72 h, or with LY294002 for 1 h. After treatment, the respective dishes were treated with EGF for 30 min or kept untreated as the control. The cells were then collected by centrifugation, and nuclear proteins were extracted as described earlier (Li and Sarkar, 2002) . Nuclear protein (10 mg) was subjected to EMSA.
NF-kB consensus double-stranded oligonucleotide (Promega) was labeled with [g-32 P]ATP using an End Labeling Kit (Invitrogen) and used as probe. Unincorporated nucleotides were removed by a chromatography column (Stratagene). In all, 10 mg of nuclear protein were preincubated with a 5 Â binding buffer (20% glycerol, 5 mm MgCl 2 , 2.5 mm EDTA, 2.5 mm DTT, 250 mm NaCl, and 50 mm Tris-HCl, 0.25 mg/ml poly (dI) : poly(dC)) for 10 min at room temperature. After the addition of 20 000 c.p.m. of 32 P-labeled NF-kB oligonucleotide, samples were incubated for an additional 20 min. The DNAprotein complexes were electrophoresed through 8% polyacrylamide gel, followed by autoradiography. To determine specific binding, unlabeled specific (NF-kB oligo) and nonspecific (androgen response element oligo) competitor oligonucleotides were used. To identify proteins in the DNAprotein complex, a supershift experiment was performed with polyclonal anti-NF-kB p50 and p65 subunit-specific antibodies (1 : 10, Geneka Biotechnology, Montre´al, Que´bec, Canada). The experiment was repeated twice.
Densitometric and statistical analysis
Autoradiogram of the Western blots and the NF-kB EMSA were scanned with a Gel Doc 1000 image scanner (Bio-Rad, Hercules, CA, USA). The bidimensional optical densities of Akt1, Akt2, phospho-Akt Ser473, phospho-GSK-3a/b, and bactin proteins on the films were quantified and analysed with the Molecular Analyst software (Bio-Rad). The ratios of Akt1/ actin, Akt2/actin, phospho-Akt Ser473/actin, and phospho-GSK-3a/b against b-actin protein expression were calculated by standardizing the ratios of each control to the unit value. The growth inhibition of MDA-MB-231 cells by genistein treatment was statistically evaluated using GraphPad Prism 2.01 (GraphPad, San Diego, CA, USA). Comparisons were made between control and genistein treatment. Po0.05 was used to indicate statistical significance.
